Clinical trials
Terminated trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,132 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 10 |
| 2006 | 2 |
| 2007 | 23 |
| 2008 | 21 |
| 2009 | 22 |
| 2010 | 17 |
| 2011 | 29 |
| 2012 | 22 |
| 2013 | 26 |
| 2014 | 34 |
| 2015 | 36 |
| 2016 | 48 |
| 2017 | 67 |
| 2018 | 79 |
| 2019 | 80 |
| 2020 | 105 |
| 2021 | 156 |
| 2022 | 140 |
| 2023 | 96 |
| 2024 | 52 |
| 2025 | 33 |
| 2026 | 22 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 1,132 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 34 |
| Sun Yat-sen University | 30 |
| Jiangsu HengRui Medicine Co., Ltd. | 29 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 26 |
| Shenzhen Geno-Immune Medical Institute | 25 |
| Hoffmann-La Roche | 24 |
| Pfizer | 22 |
| Sanofi | 21 |
| AstraZeneca | 18 |
| Fudan University | 16 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 65 |
| Breast Neoplasms | 39 |
| Carcinoma, Hepatocellular | 29 |
| Recurrence | 25 |
| Stomach Neoplasms | 24 |
| Colorectal Neoplasms | 22 |
| Neoplasms | 20 |
| Diabetes Mellitus, Type 2 | 19 |
| Leukemia, Myeloid, Acute | 19 |
| Lung Neoplasms | 17 |
Trials
Showing 76 to 100 of 1,132. Each trial links to its page on Pharma Observatory.
1,032 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.